Pfizer transplant, gastrointestinal news
Pfizer disclosed in an SEC filing that it voluntarily provided the U.S. Department of Justice and the SEC with information about potentially improper payments made by Pfizer and its Wyeth subsidiary in connection with certain sales activities outside the U.S. The DoJ is investigating Wyeth's promotional practices for gastroesophageal reflux disease (GERD) drug Protonix pantoprazole and the drug's pricing for Medicaid rebate purposes. The pharma said it is in discussions with the DoJ and SEC to resolve the issues. In addition, Pfizer said government authorities of certain foreign countries, including Germany, are investigating tax matters of an undisclosed Pfizer subsidiary.
Pfizer also disclosed that the U.S. Attorney's Office for the Western District of Oklahoma is conducting an investigation into Wyeth's promotional practices relating to off-label uses of Rapamune sirolimus. Pfizer markets the rapamycin non- calcineurin antagonist immune suppressant to prevent organ rejection in renal transplantation. ...